# Urinary Metabolic Profiling During Epileptogenesis in Rat Model of Lithium–Pilocarpine-Induced Temporal Lobe Epilepsy

**Authors:** Fatma Merve Antmen, Emir Matpan, Ekin Dongel Dayanc, Eylem Ozge Savas, Yunus Eken, Dilan Acar, Alara Ak, Begum Ozefe, Damla Sakar, Ufuk Canozer, Sehla Nurefsan Sancak, Ozkan Ozdemir, Osman Ugur Sezerman, Ahmet Tarık Baykal, Mustafa Serteser, Guldal Suyen

PMC · DOI: 10.3390/biomedicines13030588 · Biomedicines · 2025-02-27

## TL;DR

This study identifies specific urinary metabolites that change during different stages of epilepsy development in rats, offering potential biomarkers for tracking epileptogenesis.

## Contribution

The study reveals stage-specific urinary metabolic profiles during epileptogenesis in a rat model of TLE.

## Key findings

- Acute phase showed elevated acetic acid and reduced glycolysis metabolites.
- Latent phase exhibited decreased theobromine and increased 1-methylhistidine.
- Chronic phase had reduced pimelic acid and xanthurenic acid levels.

## Abstract

Background/Objectives: Temporal lobe epilepsy (TLE) often develops following an initial brain injury, where specific triggers lead to epileptogenesis—a process transforming a healthy brain into one prone to spontaneous, recurrent seizures. Although electroencephalography (EEG) remains the primary diagnostic tool for epilepsy, it cannot predict the risk of epilepsy after brain injury. This limitation highlights the need for biomarkers, particularly those measurable in peripheral samples, to assess epilepsy risk. This study investigated urinary metabolites in a rat model of TLE to identify biomarkers that track epileptogenesis progression across the acute, latent, and chronic phases and elucidate the underlying mechanisms. Methods: Status epilepticus (SE) was induced in rats using repeated intraperitoneal injections of lithium chloride–pilocarpine hydrochloride. Urine samples were collected 48 h, 1 week, and 6 weeks after SE induction. Nuclear magnetic resonance spectrometry was used for metabolomic analysis, and statistical evaluations were performed using MetaboAnalyst 6.0. Differences between epileptic and control groups were represented using the orthogonal partial least squares discriminant analysis (OPLS-DA) model. Volcano plot analysis identified key metabolic changes, applying a fold-change threshold of 1.5 and a p-value < 0.05. Results: The acute phase exhibited elevated levels of acetic acid, dihydrothymine, thymol, and trimethylamine, whereas glycolysis and tricarboxylic acid cycle metabolites, including pyruvic and citric acids, were reduced. Both the acute and latent phases showed decreased theobromine, taurine, and allantoin levels, with elevated 1-methylhistidine in the latent phase. The chronic phase exhibited reductions in pimelic acid, tiglylglycine, D-lactose, and xanthurenic acid levels. Conclusions: These findings highlight stage-specific urinary metabolic changes in TLE, suggesting distinct metabolites as biomarkers for epileptogenesis and offering insights into the mechanisms underlying SE progression.

## Linked entities

- **Chemicals:** lithium chloride (PubChem CID 433294), pilocarpine hydrochloride (PubChem CID 5909), acetic acid (PubChem CID 176), dihydrothymine (PubChem CID 93556), thymol (PubChem CID 6989), trimethylamine (PubChem CID 1146), pyruvic acid (PubChem CID 1060), citric acid (PubChem CID 311), theobromine (PubChem CID 5429), taurine (PubChem CID 1123), allantoin (PubChem CID 204), 1-methylhistidine (PubChem CID 64969), pimelic acid (PubChem CID 385), tiglylglycine (PubChem CID 6441567), D-lactose (PubChem CID 6134), xanthurenic acid (PubChem CID 5699)
- **Diseases:** epilepsy (MONDO:0005027), temporal lobe epilepsy (MONDO:0005115)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Diseases:** SE (MESH:D013226), TLE (MESH:D004833), brain injury (MESH:D001930), epilepsy (MESH:D004827), seizures (MESH:D012640)
- **Chemicals:** xanthurenic acid (MESH:C028330), thymol (MESH:D013943), acetic acid (MESH:D019342), theobromine (MESH:D013805), allantoin (MESH:D000481), 1-methylhistidine (MESH:C028120), D-lactose (-), pimelic acid (MESH:D010867), trimethylamine (MESH:C023336), Pilocarpine (MESH:D010862), taurine (MESH:D013654), tiglylglycine (MESH:C003603), Lithium (MESH:D008094), tricarboxylic acid (MESH:D014233), citric acids (MESH:D019343), lithium chloride (MESH:D018021)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11940187/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11940187/full.md

## References

100 references — full list in the complete paper: https://tomesphere.com/paper/PMC11940187/full.md

---
Source: https://tomesphere.com/paper/PMC11940187